The Infusion Providers Alliance is pleased to provide comments to CMS’ 2025 Medicare physician fee schedule proposed ruleInfusion Providers Alliance2024-09-10T13:26:06+00:00
IPA joins 45 providers and patient advocates in letter to CMS addressing access to certain biosimilar drug treatmentsInfusion Providers Alliance2024-09-10T13:29:24+00:00
The IPA strongly opposes a forthcoming “Medicaid price stacking” proposed rule (CMS-2434-P) that would impose large financial burdens on infusion providers still reeling from lack of liquidity due to the recent Change Healthcare cyber attack.Infusion Providers Alliance2024-04-02T20:32:35+00:00
The IPA is among 58 patient and provider organizations endorsing the Protecting Patient Access to Cancer and Complex Therapies Act of 2023, sponsored by Senator Barrasso and Congressmen Burgess and MurphyInfusion Providers Alliance2023-10-31T01:52:49+00:00
The IPA co-signs letter supporting the Safe Step Act (S. 652/H.R. 2630), to ensure timely consumer access to medically necessary infusion treatmentsInfusion Providers Alliance2023-11-28T18:49:10+00:00
Infusion Providers Alliance endorses the “Protecting Patient Access to Cancer and Complex Therapies Act of 2023”Infusion Providers Alliance2023-09-13T15:50:43+00:00
The Infusion Providers Alliance (IPA) is pleased to provide comments to the 2024 Medicare physician fee schedule proposed ruleInfusion Providers Alliance2023-09-12T16:09:36+00:00
IPA responds to Senate request for stakeholder input regarding the Medicare 340B Drug Discount ProgramInfusion Providers Alliance2023-07-31T22:09:37+00:00
